Compare ResMed Inc. (RMD) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wolfspeed Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Wolfspeed Inc trades at $31.6 (market cap $1.64B). The key difference: ResMed Inc. is far larger — about 19.4× Wolfspeed Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Wolfspeed Inc for 19 Days on average.
| RMD | WOLF | |
|---|---|---|
Market Cap | $31.89B | $1.64B |
Volume | 618,314 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $277.88 | $73.68 |
52-Week Low | $182.82 | $14.80 |
Typical Hold Time | 51 Days | 19 Days |
Enterprise Value | $31.24B | $2.35B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Wolfspeed (WOLF) trades at $31.37, down 1.45% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $1.61 billion in 2025, but forecasts a return to profitability in 2026 with a net income of $4 million. Recent news highlights the expansion of its 200mm silicon carbide portfolio, positioning it for growth in AI and electrification markets.
The outlook is mixed; analyst consensus is a buy with a $54.32 price target, but significant risks include negative margins, high debt, and ongoing legal investigations. Revenue growth in power devices offers upside, yet achieving breakeven remains critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
